Who Owns Akebia Company?

Akebia Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Akebia Therapeutics?

Understanding a company's ownership is key to grasping its strategic direction and market influence. Akebia Therapeutics, a biopharmaceutical firm established in 2007, has evolved significantly since its inception.

Akebia, headquartered in Cambridge, Massachusetts, initially focused on pioneering HIF-based therapies for kidney diseases. Today, it stands as a fully integrated biopharmaceutical company with two FDA-approved products, generating approximately $150 million in revenue for fiscal year 2023.

As a Nasdaq-listed company (AKBA), Akebia's ownership is spread across various institutional investors, hedge funds, and individual shareholders, reflecting its public market status.

The company's journey from its founding vision to its current public standing has seen shifts in its shareholder base. Examining these changes provides insight into how ownership influences Akebia's strategic path, including the development of treatments like those analyzed in an Akebia Porter's Five Forces Analysis.

Akebia Therapeutics was established in 2007 with the vision of developing innovative treatments for anemia. The company's founding was a collaborative effort between Marc Otte, a seasoned pharmaceutical executive, and Doug Harker, an entrepreneur with a background in biomedical ventures and angel investing.

Founding Vision

The company's initial mission centered on the discovery and advancement of novel therapeutic solutions for anemia.

Early Funding Milestones

By 2014, prior to its Initial Public Offering (IPO), the company had successfully raised over $100 million through multiple venture capital funding rounds.

Strategic Investment

This early capital infusion from strategic partners and venture capital firms was instrumental in acquiring promising assets and building a robust development and commercialization infrastructure.

Leadership Establishment

John P. Butler played a pivotal role from the outset, serving as the company's initial President and CEO, underscoring early leadership focus.

Ownership Structure Nuances

While precise initial equity distributions and shareholdings are not publicly detailed, the substantial early funding suggests a structured approach to early ownership and growth.

Developmental Foundation

The company's early agreements and specific details regarding vesting schedules or buy-sell clauses are not extensively disclosed in public records.

The early ownership of Akebia Therapeutics was shaped by its founders, Marc Otte and Doug Harker, and significantly influenced by the venture capital and strategic partners who provided crucial early-stage funding. This financial backing, exceeding $100 million by 2014, was essential for the company's initial asset acquisition and team building, laying the groundwork for its future development and market presence. The establishment of John P. Butler as the initial President and CEO further highlights the structured approach to leadership and governance from the company's inception, impacting its overall Akebia Therapeutics ownership history. Understanding the Target Market of Akebia is key to appreciating the strategic decisions made during these formative stages.

Early Ownership Dynamics

The initial ownership structure of Akebia Therapeutics was primarily driven by its founders and early investors, setting the stage for its corporate trajectory.

• Founders Marc Otte and Doug Harker established the company in 2007.
• The company's focus was on developing treatments for anemia.
• Significant early funding, over $100 million by 2014, came from venture capital and strategic partners.
• John P. Butler served as the initial President and CEO, indicating early leadership.
• Specific early equity splits and vesting details are not widely publicized.

Akebia SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Akebia Therapeutics became a publicly traded entity on March 20, 2014, through an initial public offering that raised approximately $100 million. This event marked a significant shift in its ownership structure, moving from private to public hands and enabling further capital for its development initiatives.

The ownership landscape of Akebia Therapeutics is characterized by a significant presence of institutional investors, alongside substantial holdings by individual and retail investors. Company insiders also maintain a notable stake, reflecting their commitment to the company's trajectory. Understanding these Akebia company stakeholders is key to grasping the dynamics of Akebia stock ownership.

Akebia Therapeutics: Key Ownership Details

As of July 24, 2025, Akebia Therapeutics has a diverse shareholder base, with institutional investors playing a prominent role. Recent trends indicate an increasing institutional interest in the company.

• 279 institutional owners and shareholders have filed with the SEC.
• Institutional ownership stands at approximately 44.21%.
• Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, and State Street Corp.
• Muneer A. Satter is the largest individual shareholder, holding 5.04 million shares, or 1.92% of the company.
• The number of institutional owners grew by 15.23% in the last quarter.

The evolution of Akebia Therapeutics' ownership structure is a story of growth and increasing investor confidence. From its IPO in 2014, the company has attracted a broad range of investors, including major financial institutions and individual shareholders. This increasing institutional ownership, with a 12.33% rise in total shares owned by institutions in the quarter ending April 1, 2025, highlights the growing appeal of Akebia Therapeutics. For those interested in the company's journey, a Brief History of Akebia provides further context on its development and strategic milestones.

Akebia PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Akebia Therapeutics board of directors is responsible for overseeing the company's strategic direction and corporate governance. As of July 2025, key members include Chairperson Adrian Adams and President, CEO & Director John P. Butler, alongside directors Ron Frieson, Steven C. Gilman, Ph.D., Michael Rogers, Cynthia Smith, Myles Wolf, M.D., M.M.Sc., and LeAnne M. Zumwalt.

The board is structured with several committees to manage specific areas of oversight. These include the Audit Committee, Compensation Committee, Nominating & Corporate Governance Committee, and Research & Development Committee. For instance, LeAnne M. Zumwalt serves on both the Audit Committee and the Nominating & Corporate Governance Committee, while Steven C. Gilman, Ph.D., is involved with the Compensation Committee and the Research & Development Committee. The voting power for Akebia Therapeutics is generally one vote per outstanding share of common stock. The company's 2025 Annual Meeting on June 10, 2025, focused on important matters like electing Class II directors and approving an amendment to the 2023 Stock Incentive Plan to add 18,900,000 shares, which could impact Akebia stock ownership for current shareholders.

Board Committees and Director Contributions

Board committees are vital for specialized oversight. Key directors contribute their expertise across these critical functions.

• Audit Committee: Ron Frieson, Michael Rogers, LeAnne M. Zumwalt
• Compensation Committee: Steven C. Gilman, Ph.D., Cynthia Smith
• Nominating & Corporate Governance Committee: LeAnne M. Zumwalt, Myles Wolf, M.D., M.M.Sc.
• Research & Development Committee: Steven C. Gilman, Ph.D., Myles Wolf, M.D., M.M.Sc.
• Understanding the Mission, Vision & Core Values of Akebia provides context for board decisions.

Akebia Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Akebia Therapeutics has seen significant shifts in its ownership over the past few years, with a notable increase in institutional investor participation. This trend is partly driven by strategic financial maneuvers and the company's focus on key product commercialization.

The company's financial health has been bolstered by recent capital raises, enhancing its operational capacity. As of March 31, 2025, Akebia reported cash and cash equivalents of approximately $113.4 million, a substantial increase from $51.9 million at the end of 2024. This growth is partly attributable to the net proceeds of $46.5 million from a public offering completed in March 2025, which involved the sale of 25 million common stock shares at $2.00 per share. This influx of capital has contributed to an expanding institutional investor base, a key trend in Akebia Therapeutics ownership.

Institutional Ownership Growth

As of July 24, 2025, 279 institutional owners held 116,118,346 shares, representing 44.21% of outstanding shares. This signifies a 15.23% increase in institutional owners in the most recent quarter.

Key Institutional Investors

Major institutional buyers in Q1 2025 included Great Point Partners LLC, AIGH Capital Management LLC, and Franklin Resources Inc., all of whom significantly increased their positions.

Strategic Focus on Vafseo

The company's strategic direction is largely centered on the global commercialization of Vafseo (vadadustat), approved by the U.S. FDA in March 2023. Vafseo generated $12.0 million in net product revenues in Q1 2025.

Future Label Expansion

Akebia Therapeutics is planning to initiate a Phase 3 trial in mid-2025. This trial aims to potentially broaden Vafseo's approved use to include adult patients with anemia due to CKD who are not on dialysis.

Recent insider transactions, such as the inducement grants of stock options to new employees, also highlight ongoing activity within the company's ownership structure. These grants, including 137,000 stock options to three new hires as of June 2, 2025, reflect the company's efforts to attract and retain talent. For a deeper understanding of the company's strategic direction, one might review the Marketing Strategy of Akebia. The company's annual report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent filings provide comprehensive updates on Akebia Therapeutics financial reports and company structure.

Akebia Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔